A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Abali, HuseyinYalcin, SuayibOnal, CemDane, FaysalOksuzoglu, BernaOzdemir, NuriyeMertsoylu, Huseyin2024-03-132024-03-1320180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.4_suppl.26https://hdl.handle.net/20.500.12662/3397Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) -- JAN 18-20, 2018 -- San Francisco, CA[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessA study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).Conference Object10.1200/JCO.2018.36.4_suppl.26436WOS:000436174100026Q1